Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.75 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.69 |
| ▸ | USP2 | O75604 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | HAT1 | O14929 | 4/20 | 0.69 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | RECQL | P46063 | 3/20 | 0.69 |
| ▸ | CASP7 | P55210 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | CASP1 | P29466 | 2/20 | 0.69 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | TST | Q16762 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293291 | 0.99 | ESR1 (0.77) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| SCHEMBL24238132 | 0.96 | ESR1 (0.78) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| SCHEMBL14598781 | 0.89 | ESR1 (0.67) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL1532396 | 0.86 | ESR1 (1.00) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL297863 | 0.86 | ESR1 (1.00) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL41133 | 0.86 | ESR1 (1.00) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL190079 | 0.86 | ESR1 (1.00) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin SCHEMBL20528621 | 0.86 | MEN1 (0.90) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| SCHEMBL6369069 | 0.85 | MEN1 (0.73) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL6681480 | 0.85 | ESR1 (0.98) | ESR1NR3C1ADRB2HTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822604-B1 | COLORING SUBSTANCE FOR DIAGNOSTIC OPHTALMOLOGIC USE | IROS R C S R L (IT) | 2018-09-05 | — | — | EP | claimed |
| US-9370587-B2 | Coloring substance for diagnostic ophtalmologic use | Caruso, Ciro (IT) | 2016-06-21 | — | — | US | claimed |
| EP-2822604-A1 | COLORING SUBSTANCE FOR DIAGNOSTIC OPHTALMOLOGIC USE | Iros R.C. S.r.l. (IT) | 2015-01-14 | — | — | EP | claimed |
| US-20140371569-A1 | COLORING SUBSTANCE FOR DIAGNOSTIC OPHTALMOLOGIC USE | IROS R.C. S.R.L. (IT) | 2014-12-18 | — | — | US | claimed |
| WO-2013132396-A1 | COLORING SUBSTANCE FOR DIAGNOSTIC OPHTALMOLOGIC USE | DEL PRETE, ANTONIO (IT) | 2013-09-12 | — | — | WO | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | claimed |
| US-6444221-B1 | ADMINISTERING AMINOBENZOIC ACID | SECANT PHARMA, LLC | 2002-09-03 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-7501138-B2 | Liquid food/drink containing fat-soluble vitamin and method of stabilizing fat-soluble vitamin | KYOWA HAKKO FOOD SPECIALITIES CO., LTD. (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | disclosed |
| EP-1841460-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-10-10 | — | — | EP | disclosed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | disclosed |
| US-6444221-B1 | ADMINISTERING AMINOBENZOIC ACID | SECANT PHARMA, LLC | 2002-09-03 | — | — | US | disclosed |
| EP-0523582-B1 | Improved process for preparing riboflavin 5'-phosphate ester monosodium salt | BASF AG (DE) | 1998-10-14 | — | — | EP | disclosed |
| EP-0523582-A1 | Improved process for preparing riboflavin 5'-phosphate ester monosodium salt | BASF Aktiengesellschaft (DE) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | ESR1 3419/4885NR3C1 2106/4885ADRB2 2787/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | ESR1 3494/4885NR3C1 2322/4885ADRB2 3072/4885 |
| US-20140371569-A1 | COLORING SUBSTANCE FOR DIAGNOSTIC OPHTALMOLOGIC USE | ALDH1A2, ADH1B, ADH7 | ESR1 3682/4885NR3C1 1717/4885ADRB2 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.